Dr. Reddy's completes acquisition of 8 Teva generics

HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories this week announced that it had completed its previously announced acquisition of eight Abbreviated New Drug Applications (ANDAs) from Teva and an Allergan affiliate. 

 

The products include six ANDAs awaiting approval, as well as one tentatively approved products. They are a generics of Suboxone (buprenorphine HCl/Naloxone HCL) sublingual film; NuvaRing (ethinyl estradiol/ethonogestrel vaginal ring); Vytorin (ezetimibe/simvastatin) tablets; Kombiglyze XR (metformin HCl/saxaglipton) extended-release tablets; Tobi (tobramycin inhalation solution), Qsymia (phentermine HCl/topiramate) extended-release capsules; Zyclara (imiquimod 3.75% topical cream); and Rozerem (ramelteon) tablets. 

 

The products have combined U.S. sales of $3.5 billion for the 12 months ended June 2016, according to IMS Health.